Poliklinika Solmed
Zagreb 10000
5 studies enrolling now · 13 studies all time
What they study most
Acute Coronary Syndrome, Atrial Fibrillation, Bullous Pemphigoid, Crohn Disease, Crohn's Disease, Diabetes Mellitus, Diabetes Mellitus, Type 2, Inflammatory Bowel Diseases, Obesity, Overweight, Relapsing Multiple Sclerosis, Type 2 Diabetes
Studies at this site
- AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Recruiting now
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis — Recruiting now
- A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Recruiting now
- A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes — Recruiting now
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
- A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide — Running, not enrolling
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
- A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
- A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
- AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Starting soon
- A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid — Stopped early
- The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis — Stopped early